Dernières nouvelles pour Molina Healthcare (NYSE:MOH) Stock

MOLINA HEALTHCARE INC

Molina Healthcare

Molina Healthcare Inc offers healthcare plans focused on Medicaid-related solutions for low-income families and individuals. Its health plans are operated by a network of subsidiaries, each of which is licensed as a health maintenance organization (HMO). It has four segments: Medicaid, Medicare, Marketplace and Others. The Medicaid, Medicare, and Marketplace segments represent the government-funded or sponsored programs under which it offers managed healthcare services. The Other segment, which is insignificant to its consolidated results of operations, includes long-term services and supports consultative services in Wisconsin. It generates majority revenue from Medicaid segment.

Molina Healthcare Inc

MOTOR OIL HELLAS CORINTH by Motor Oil (Hellas) Corinth Refineries S.A.

Motor Oil (Hellas) Corinth Refineries SA

MOTOR OIL HELLAS UNSP/ADR by Motor Oil (Hellas) Corinth Refineries S.A.

Collaborative Investment Series Trust Mohr Growth ETF

Mohawk Industries Inc

Shares of managed care provider Centene Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNC#NYSE">CNC</a>) dropped over 40% on Wednesday, marking the worst single-day performance in the company's history.
Check out the current price of&nbsp;<a href="https://www.benzinga.com/quote/CNC" target="_blank" rel="noreferrer noopener">CNC stock here.</a>
What Happened: On CNBC&#8217;s Mad Money, Jim Cramer referred to the collapse as &#8220;a huge hit,&#8221; resulting from a combination of factors such as weak Affordable Care Act enrollments, an actuarial report pointing to sicker patients, and the company&#8217;s decision to <a href="https://www.benzinga.com/markets/guidance/25/07/46209736/centene-withdraws-2025-guidance-shares-dive">pull its 2025 outlook</a>.
&#8220;Companies make forecasts, they&#8217;re supposed to try and beat them,&#8221; Cramer says, however, &#8220;they rarely pull them.&#8221;
According to Cramer, Centene disclosed data from an independent actuarial firm covering 22 of the 29 states where it operates ACA exchange plans.
See Also: <a href="https://www.benzinga.com/markets/macro-economic-events/25/07/46195080/doj-dismantles-14-billion-healthcare-fraud-scheme-in-largest-ever-crackdown-impacting-over-1-million-americans">DOJ Dismantles $14 Billion Healthcare Fraud Scheme In Largest-Ever Crackdown, Impacting Over 1 Million Americans</a>
The findings showed that overall marketplace enrollment growth was lower than expected and that those who did enroll were in poorer health than projected, a combination that significantly affects the company's bottom line, thus prompting the company to pull its guidance.
As a result, the company now expects a $1.8 billion reduction in its projected risk adjustment revenue from the federal government. This drop is expected to slash its 2025 earnings by $2.75 per share.
&#8220;This is horrifying,&#8221; Cramer said, referring to the sharp revision in Centene&#8217;s EPS, from $7.25 per share projected earlier. &#8220;We&#8217;re talking about a 35% to 40% hit to their numbers,&#8221; Cramer says, &#8220;no wonder the stock was eviscerated.&#8221;
Why It Matters: Centene&#8217;s decision to withdraw its guidance, citing the independent actuarial report, led to a sector-wide selloff on Wednesday. 
All of Centene&#8217;s peers and competitors in the managed care business, such as Molina Healthcare Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MOH#NYSE">MOH</a>), Elevance Health Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ELV#NYSE">ELV</a>), UnitedHealth Group Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>), and Cigna Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CI#NYSE">CI</a>), among others, all falling in tandem during the day. 
<figure class="wp-block-table"> 
<table class="has-fixed-layout">
<tbody>
<tr>
<td class="has-text-align-center" data-align="center">Stocks / ETFs</td>
<td class="has-text-align-center" data-align="center">1 Day</td>
<td class="has-text-align-center" data-align="center">Year-To-Date</td>
</tr>
<tr>
<td class="has-text-align-center" data-align="center">Centene Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNC#NYSE">CNC</a>)</td>
<td class="has-text-align-center" data-align="center">-40.37%</td>
<td class="has-text-align-center" data-align="center">-44.17%</td>
</tr>
<tr>
<td class="has-text-align-center" data-align="center">Molina Healthcare Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MOH#NYSE">MOH</a>)</td>
<td class="has-text-align-center" data-align="center">-21.97%</td>
<td class="has-text-align-center" data-align="center">-16.79%</td>
</tr>
<tr>
<td class="has-text-align-center" data-align="center">Elevance Health Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ELV#NYSE">ELV</a>)</td>
<td class="has-text-align-center" data-align="center">-11.50%</td>
<td class="has-text-align-center" data-align="center">-4.26%</td>
</tr>
<tr>
<td class="has-text-align-center" data-align="center">UnitedHealth Group Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>)</td>
<td class="has-text-align-center" data-align="center">-5.70%</td>
<td class="has-text-align-center" data-align="center">-39.04%</td>
</tr>
<tr>
<td class="has-text-align-center" data-align="center">Cigna Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CI#NYSE">CI</a>)</td>
<td class="has-text-align-center" data-align="center">-4.19%</td>
<td class="has-text-align-center" data-align="center">+16.72%</td>
</tr>
<tr>
<td class="has-text-align-center" data-align="center">iShares US Healthcare Providers ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IHF#NYSE">IHF</a>)</td>
<td class="has-text-align-center" data-align="center">-6.27%</td>
<td class="has-text-align-center" data-align="center">-3.16%</td>
</tr>
</tbody>
</table>
</figure>
This comes amid a potential amendment in the Affordable Care Act, which could lead to an additional $313 billion in <a href="https://www.benzinga.com/markets/macro-economic-events/25/06/46163659/senate-republicans-propose-313-billion-cut-in-medicaid-spending-in-trumps-big-beautiful-bill">spending cuts</a> by blocking able-bodied adults without dependent children in Medicaid expansion states from receiving the enhanced 9-to-1 Federal Medical Assistance Percentage (FMAP).
Insurers have also <a href="https://www.benzinga.com/personal-finance/tax/25/06/46012776/brace-for-higher-healthcare-premiums-in-2026-as-insurers-blame-trumps-tariffs-in-filings-to-regulators-report">warned of higher premiums</a> in 2026, placing the blame on President Donald Trump&#8217;s tariffs, which are expected to increase the cost&nbsp;of prescription drugs, medical devices,&nbsp;and other medical products and&nbsp;services.
Price Action: Shares of Centene dropped 40.37% on Wednesday, closing at $33.78, but are up 1.10% after hours.
<figure class="wp-block-image size-large"><a href="https://www.benzinga.com/premium/ideas/benzinga-edge-2#:~:text=Turn%20Market%20Chaos,when%20markets%20rebound"><img loading="lazy" decoding="async" width="1024" height="143" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/02234828/Screenshot-2025-07-03-at-9.18.15-AM-1024x143.png" alt="" class="wp-image-971299" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/02234828/Screenshot-2025-07-03-at-9.18.15-AM-1024x143.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/02234828/Screenshot-2025-07-03-at-9.18.15-AM-300x42.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/02234828/Screenshot-2025-07-03-at-9.18.15-AM-768x107.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/02234828/Screenshot-2025-07-03-at-9.18.15-AM.png 1532w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
According to Benzinga&#8217;s Edge Stock Rankings, Centene scores well on Value and Growth, but has an unfavorable price trend in the short, medium and long term. Click <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-2#:~:text=Turn%20Market%20Chaos,when%20markets%20rebound">here</a> for deeper insights on the stock, as well as its peers and competitors in the managed care space.
Photo courtesy: katz / Shutterstock.com
Read More: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/personal-finance/management/25/06/46166087/mark-cuban-slams-insurers-over-high-deductibles-urges-josh-hawley-to-change-the-game-with-two-part-plan">Mark Cuban Slams Insurers Over High Deductibles, Urges Josh Hawley To &#8216;Change The Game&#8217; With Two-Part Plan</a></li>
</ul>

News

Guidance

Markets

streetTRACKS Dow Jones U.S. Large Cap Value Index Fund

iShares Dow Jones US Health Care Provides Index Fund

Jim Cramer On Centene's 40% Crash: Fewer ACA Signups, Sicker Patients, Pulled Guidance And Major Earnings Hit Trigger Selloff: 'This Is Horrifying'

<h3>Gainers</h3>
<ul>
<li>Sonnet BioTherapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SONN#NASDAQ">SONN</a>) stock moved upwards by 82.6% to $2.21 during Wednesday's regular session. The market value of their outstanding shares is at $3.8 million. </li>
<li>Lixte Biotechnology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LIXT#NASDAQ">LIXT</a>) stock moved upwards by 49.15% to $1.76. The market value of their outstanding shares is at $3.2 million. </li>
<li>Eyenovia (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EYEN#NASDAQ">EYEN</a>) shares moved upwards by 40.9% to $14.88. The market value of their outstanding shares is at $53.9 million. </li>
<li>NeOnc Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTHI#NASDAQ">NTHI</a>) stock increased by 31.34% to $4.4. The company's market cap stands at $63.7 million. </li>
<li>Nutriband (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTRB#NASDAQ">NTRB</a>) shares moved upwards by 27.93% to $10.26. The market value of their outstanding shares is at $89.2 million. </li>
<li>Windtree Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WINT#NASDAQ">WINT</a>) shares moved upwards by 25.39% to $0.69. The company's market cap stands at $2.0 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Centene (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNC#NYSE">CNC</a>) shares decreased by 39.6% to $34.19 during Wednesday's regular session. The market value of their outstanding shares is at $28.1 billion. </li>
<li>Mustang Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MBIO#NASDAQ">MBIO</a>) stock decreased by 38.44% to $1.26. The company's market cap stands at $8.9 million. </li>
<li>Regencell Bioscience (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGC#NASDAQ">RGC</a>) shares decreased by 27.37% to $10.61. The company's market cap stands at $7.2 billion. As per the news, the H1 earnings report came out 2 days ago. </li>
<li>CytoSorbents (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTSO#NASDAQ">CTSO</a>) stock declined by 25.82% to $0.96. The market value of their outstanding shares is at $80.7 million. </li>
<li>Cyclacel Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYCC#NASDAQ">CYCC</a>) stock declined by 20.43% to $0.27. The market value of their outstanding shares is at $7.9 million. </li>
<li>Molina Healthcare (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MOH#NYSE">MOH</a>) shares declined by 20.18% to $244.5. The market value of their outstanding shares is at $16.6 billion. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

CTSO

CYCC

EYEN

LIXT

MBIO

NTHI

NTRB

SONN

WINT

12 Health Care Stocks Moving In Wednesday's Intraday Session

U.S. stocks traded mixed midway through trading, with the Nasdaq Composite gaining around 150 points on Wednesday.
The Dow traded down 0.10% to 44,450.62 while the NASDAQ gained 0.78% to 20,360.92. The S&amp;P 500 also rose, gaining, 0.25% to 6,213.50.
Check This Out: <a href="https://www.benzinga.com/trading-ideas/dividends/25/07/46218048/how-to-earn-500-a-month-from-microsoft-stock-4">How To Earn $500 A Month From Microsoft Stock</a>
Leading and Lagging Sectors Information technology shares jumped by 1% on Wednesday.
In trading on Wednesday, utilities stocks fell by 1.3%.
Top Headline 
U.S. crude oil inventories increased by 3.845 million barrels in the week ended June 27, versus market estimates of a 2 million barrel decline.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul class="wp-block-list">
<li>Hut 8 Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HUT#NASDAQ">HUT</a>) shares shot up 15% to $21.27 after announcing a key infrastructure win in Ontario.</li>
<li>Shares of Mogo Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MOGO#NASDAQ">MOGO</a>) got a boost, surging 105% to $2.4800 after the company announced a $50 million bitcoin treasury authorization.</li>
<li>The Greenbrier Companies, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GBX#NYSE">GBX</a>) shares were also up, gaining 18% to $55.58 after the company posted stronger-than-expected results for the third quarter.</li>
</ul>
Equities Trading DOWN
<ul class="wp-block-list">
<li>Oscar Health, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OSCR#NYSE">OSCR</a>) shares dropped 15% to $17.49 after Barclays initiated coverage with an Underweight rating and announced a price target of $17.</li>
<li>Shares of Molina Healthcare, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MOH#NYSE">MOH</a>) were down 18% to $250.80. Shares of health insurance stocks traded lower in sympathy with Centene, which withdrew its 2025 guidance.</li>
<li>Centene Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNC#NYSE">CNC</a>) was down, falling 38% to $34.45 after the company withdrew its previous 2025 GAAP and adjusted diluted EPS guidance, including the underlying guidance elements.</li>
</ul>
Commodities In commodity news, oil traded up 1.5% to $66.44 while gold traded up 0.1% at $3,354.00.
Silver traded up 0.7% to $36.635 on Wednesday, while copper rose 1.6% to $5.1820.
Euro zone
European shares were mostly higher today. The eurozone's STOXX 600 rose 0.13%, while Spain's IBEX 35 Index rose 0.35%. London's FTSE 100 fell 0.24%, Germany's DAX 40 gained 0.51% and France's CAC 40 gained 1.06% during the session.
Asia Pacific Markets
Asian markets closed lower on Wednesday, with Japan's Nikkei dipping 0.56%, China's Shanghai Composite falling 0.09% and India's BSE Sensex falling 0.34%.
Economics
<ul class="wp-block-list">
<li>U.S.-based employers announced job cuts of 47,999 in June versus 93,816 in the previous month and 48,786 in the year-ago period.</li>
<li>The volume of mortgage applications increased by 2.7% from the previous week during the last week of June.</li>
<li>U.S. crude oil inventories increased by 3.845 million barrels in the week ended June 27, versus market estimates of a 2 million barrel decline.</li>
</ul>
Now Read This: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/25/07/46192054/cramer-backs-this-mining-giant-after-1-6b-bet">Cramer Backs This Mining Giant After $1.6B Bet</a> </li>
</ul>
Photo via Shutterstock

Equities

Eurozone

Commodities

Intraday Update

Trading Ideas

MOGO

OSCR

Crude Oil Gains 1.5%; Greenbrier Shares Spike Higher

U.S. stock futures were higher this morning, with the Dow futures gaining around 0.2% on Wednesday.
Shares of Centene Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNC#NYSE">CNC</a>) fell sharply in today's pre-market trading after the health<a href="https://www.benzinga.com/quote/CNC"> care company withdrew its guidance for 2025.</a>
Centene withdrew its previous 2025 earnings guidance and all underlying guidance elements based on the company's preliminary interpretation of marketplace data from the independent actuarial firm Wakely.
Centene shares dipped 27.7% to $40.94 in the pre-market trading session.
Here are some other stocks moving lower in pre-market trading.
<ul class="wp-block-list">
<li>Molina Healthcare, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MOH#NYSE">MOH</a>) tumbled 9% to $278.89 in pre-market trading.</li>
<li>BrightView Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BV#NYSE">BV</a>) dipped 8.8% to $15.37 in pre-market trading after the company lowered its FY25 revenue guidance from $2.75–$2.84 billion to $2.68–$2.73 billion.</li>
<li>Oscar Health, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OSCR#NYSE">OSCR</a>) shares fell 8.3% to $18.75 in pre-market trading after dipping 5% on Tuesday.</li>
<li>Mesoblast Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MESO#NASDAQ">MESO</a>) fell 7.4% to $11.22 in pre-market trading. Mesoblast shares gained 11% on Tuesday after the company announced it is targeting an accelerated FDA approval for its heart failure drug Revascor.</li>
<li>ArriVent BioPharma, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVBP#NASDAQ">AVBP</a>) fell 5.4% to $19.76 in pre-market trading as the company announced the pricing of $75 million public offering of common stock and pre-funded warrants.</li>
<li>DeFi Development Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DFDV#NASDAQ">DFDV</a>) dipped 4.6% to $20.05 in pre-market trading after the company announced plans for a $100 million convertible notes offering.</li>
</ul>
Now Read This: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/25/07/46192054/cramer-backs-this-mining-giant-after-1-6b-bet">Cramer Backs This Mining Giant After $1.6B Bet</a></li>
</ul>
Photo via Shutterstock

Pre-Market Outlook

AVBP

DFDV

MESO

Centene, BrightView Holdings, ArriVent BioPharma And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session

WIIM

Shares of health insurance stocks are trading lower in sympathy with Centene, which withdrew its 2025 guidance.

Molina Healthcare (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MOH#NYSE">MOH</a>) has outperformed the market over the past 15 years by 8.06% on an annualized basis producing an average annual return of 20.52%. Currently, Molina Healthcare has a market capitalization of $14.91 billion. 
Buying $1000 In MOH: If an investor had bought $1000 of MOH stock 15 years ago, it would be worth $16,670.36 today based on a price of $275.02 for MOH at the time of writing.
<h3>Molina Healthcare's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1751406310_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much You Would Have Made Owning Molina Healthcare Stock In The Last 15 Years

<a href="https://www.reuters.com/legal/litigation/us-supreme-court-expected-rule-obamacare-preventive-care-task-force-2025-06-27/" title="https://www.reuters.com/legal/litigation/us-supreme-court-expected-rule-obamacare-preventive-care-task-force-2025-06-27/">https://www.reuters.com/legal/litigation/us-supreme-court-expected-rule-obamacare-preventive-care-task-force-2025-06-27/</a>
&nbsp;

General

ALHC

CLOV

'US Supreme Court preserves key element of Obamacare preventive care'- Reuters

Molina Healthcare (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MOH#NYSE">MOH</a>) has outperformed the market over the past 15 years by 7.54% on an annualized basis producing an average annual return of 19.56%. Currently, Molina Healthcare has a market capitalization of $15.87 billion. 
Buying $1000 In MOH: If an investor had bought $1000 of MOH stock 15 years ago, it would be worth $14,429.86 today based on a price of $292.83 for MOH at the time of writing.
<h3>Molina Healthcare's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1750082419_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

If You Invested $1000 In This Stock 15 Years Ago, You Would Have This Much Today

Barclays analyst Andrew Mok maintains Molina Healthcare (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MOH#NYSE">MOH</a>) with a Equal-Weight and lowers the price target from $351 to $347.

Price Target

Analyst Ratings

Barclays Maintains Equal-Weight on Molina Healthcare, Lowers Price Target to $347

Morgan Stanley analyst Erin Wright initiates coverage on Molina Healthcare (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MOH#NYSE">MOH</a>) with a Overweight rating and announces Price Target of $364.

Initiation

Morgan Stanley Initiates Coverage On Molina Healthcare with Overweight Rating, Announces Price Target of $364

Molina Healthcare (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MOH#NYSE">MOH</a>) has been analyzed by 7 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $382.0, a high estimate of $414.00, and a low estimate of $351.00. This upward trend is evident, with the current average reflecting a 12.19% increase from the previous average price target of $340.50.
<img src="https://www.benzinga.com/files/images/story/2025/1748901618_0.png" alt="price target chart" />
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive Molina Healthcare. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Andrew Mok</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$351.00</td>
<td>$362.00</td>
</tr>
<tr>
<td>Andrew Mok</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$362.00</td>
<td>$339.00</td>
</tr>
<tr>
<td>Lance Wilkes</td>
<td>Bernstein</td>
<td>Announces</td>
<td>Outperform</td>
<td>$414.00</td>
<td>-</td>
</tr>
<tr>
<td>Michael Ha</td>
<td>Baird</td>
<td>Raises</td>
<td>Neutral</td>
<td>$375.00</td>
<td>$331.00</td>
</tr>
<tr>
<td>David Macdonald</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$400.00</td>
<td>$340.00</td>
</tr>
<tr>
<td>Ann Hynes</td>
<td>Mizuho</td>
<td>Raises</td>
<td>Outperform</td>
<td>$400.00</td>
<td>$376.00</td>
</tr>
<tr>
<td>Stephen Baxter</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$372.00</td>
<td>$295.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Molina Healthcare. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Molina Healthcare compared to the broader market.</li>
<li>Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of Molina Healthcare's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Capture valuable insights into Molina Healthcare's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/MOH/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Molina Healthcare analyst ratings.</a>
<h2>Unveiling the Story Behind Molina Healthcare</h2>
Molina Healthcare Inc offers healthcare plans focused on Medicaid-related solutions for low-income families and individuals. Its health plans are operated by a network of subsidiaries, each of which is licensed as a health maintenance organization (HMO). It has four segments: Medicaid, Medicare, Marketplace and Others. The Medicaid, Medicare, and Marketplace segments represent the government-funded or sponsored programs under which it offers managed healthcare services. The Other segment, which is insignificant to its consolidated results of operations, includes long-term services and supports consultative services in Wisconsin. It generates majority revenue from Medicaid segment.
<h3>Molina Healthcare: Financial Performance Dissected</h3>
Market Capitalization Analysis: The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.
Positive Revenue Trend: Examining Molina Healthcare's financials over 3M reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 12.24% as of 31 March, 2025, showcasing a substantial increase in top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Molina Healthcare's net margin is below industry standards, pointing towards difficulties in achieving strong profitability. With a net margin of 2.67%, the company may encounter challenges in effective cost control.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of 6.77%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): Molina Healthcare's ROA stands out, surpassing industry averages. With an impressive ROA of 1.86%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: Molina Healthcare's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.87.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Beyond The Numbers: 7 Analysts Discuss Molina Healthcare Stock

Molina Healthcare shares are trading lower after Barclays maintained an Equal-Weight rating on the stock but lowered its price target from $362 to $351.

Barclays analyst Andrew Mok maintains Molina Healthcare (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MOH#NYSE">MOH</a>) with a Equal-Weight and lowers the price target from $362 to $351.

Barclays Maintains Equal-Weight on Molina Healthcare, Lowers Price Target to $351

Molina Healthcare (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MOH#NYSE">MOH</a>) has outperformed the market over the past 20 years by 4.37% on an annualized basis producing an average annual return of 12.58%. Currently, Molina Healthcare has a market capitalization of $16.87 billion. 
Buying $100 In MOH: If an investor had bought $100 of MOH stock 20 years ago, it would be worth $1,069.73 today based on a price of $311.27 for MOH at the time of writing.
<h3>Molina Healthcare's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1748035829_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much $100 Invested In Molina Healthcare 20 Years Ago Would Be Worth Today

Molina Healthcare (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MOH#NYSE">MOH</a>) has outperformed the market over the past 20 years by 4.59% on an annualized basis producing an average annual return of 12.84%. Currently, Molina Healthcare has a market capitalization of $17.31 billion. 
Buying $100 In MOH: If an investor had bought $100 of MOH stock 20 years ago, it would be worth $1,118.60 today based on a price of $319.29 for MOH at the time of writing.
<h3>Molina Healthcare's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1747863926_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much You Would Have Made Owning Molina Healthcare Stock In The Last 20 Years

Shares of health insurers are trading higher. The sector may be volatile following recent reports of an investigation into UNH, which the company denied.

&#8216;The Big Short&#8217; famed investor Michael Burry, who accurately predicted the 2008 housing market crash, has turned bearish on most equities while doubling his stake in cosmetics giant Estée Lauder Companies Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EL#NYSE">EL</a>) during the first quarter, according to 13F regulatory filings with the Securities and Exchange Commission on Thursday.
What Happened: Burry&#8217;s Scion Asset Management increased its position in Estée Lauder to 200,000 shares from 100,000 shares at the end of the fourth quarter, despite EL stock being down 13.94% this year. The move comes as the beauty company pursues its &#8220;Beauty Reimagined&#8221; <a href="https://www.benzinga.com/25/05/45179419/estee-lauders-beauty-gains-cant-offset-global-headwinds-says-analyst">recovery strategy amid global headwinds</a>.
EL stock closed at $63.67 on Thursday, down 0.69% for the day. In after-hours trading, the stock rose 3.85% to $66.12, according to <a href="https://pro.benzinga.com/dashboard">data from Benzinga Pro</a>.
The 13F report revealed significant portfolio adjustments, including Scion taking a substantial bearish position on artificial intelligence leader NVIDIA Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) through 900,000 put options. NVIDIA shares have retreated from their January all-time high of $153.13 amid macroeconomic concerns and worries about tariff impacts.
See Also: <a href="https://www.benzinga.com/markets/cryptocurrency/25/05/45460177/bitcoin-rises-while-ethereum-dogecoin-slip-market-isnt-going-to-peak-in-the-next-6-months-says-popular-analyst">Bitcoin Rises While Ethereum, Dogecoin Slip — &#8216;Market Isn&#8217;t Going To Peak In The Next 6 Months,&#8217; Says Popular Analyst</a>
Why It Matters: Burry also completely liquidated his positions in Chinese tech companies, including Alibaba Group Holding Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BABA#NYSE">BABA</a>), Baidu Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIDU#NASDAQ">BIDU</a>), JD.com Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JD#NASDAQ">JD</a>), and PDD Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PDD#NASDAQ">PDD</a>). 
This exit coincides with President Donald Trump&#8216;s April announcement of hefty import tariffs targeting China, though both nations recently agreed to <a href="https://www.benzinga.com/25/04/44946516/goldman-sachs-ceo-says-trumps-90-day-tariff-pause-increased-the-level-of-uncertainty-triggered-market-repricing">suspend reciprocal levies for 90 days</a>.
The hedge fund manager also exited healthcare positions in HCA Healthcare Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HCA#NYSE">HCA</a>), Oscar Health Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OSCR#NYSE">OSCR</a>), and Molina Healthcare Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MOH#NYSE">MOH</a>).
Analysts note that while Estée Lauder delivered <a href="https://www.benzinga.com/25/05/45179419/estee-lauders-beauty-gains-cant-offset-global-headwinds-says-analyst">stronger-than-expected third quarter earnings</a> with improved margins and cost control, the company still faces challenges, particularly in Asia travel retail and a softening North American market.
Photo Courtesy: Sorbis On Shutterstock.com
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/25/05/45459474/sounds-familiar-mohamed-el-erian-calls-out-powells-deja-vu-on-supply-shocks-economist-draws-historic-parallels-on-fed-chairs-latest-message">&#8216;Sounds Familiar?&#8217; Mohamed El-Erian Calls Out Powell&#8217;s Déjà Vu On Supply Shocks—Economist Draws Historic Parallels On Fed Chair&#8217;s Latest Message</a></li>
</ul>
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

BABA

BIDU

NVDA

Citigourp Global Markets 2% Protected Notes Linked To The Djia

'The Big Short' Fame Michael Burry Doubled Estée Lauder Stake Despite Slump, Bet Against Nvidia And Dumps China Stocks Amid Trade War Jitters In Q1

iShares Trust Dow Jones US Healthcare Sector Index Fund

Shares of health insurance stocks are trading lower after UnitedHealth suspended its 2025 outlook as medical expenditures were expected to be larger than anticipated.

Molina Healthcare's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MOH#NYSE">MOH</a>) short percent of float has fallen 26.75% since its last report. The company recently reported that it has 954 thousand shares sold short, which is 2.3% of all regular shares that are available for trading. Based on its trading volume, it would take traders 1.0 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>Molina Healthcare Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1747065633_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Molina Healthcare has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Molina Healthcare's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, Molina Healthcare's peer group average for short interest as a percentage of float is 4.68%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

Is Molina Healthcare Gaining or Losing Market Support?

Molina Healthcare (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MOH#NYSE">MOH</a>) has outperformed the market over the past 10 years by 6.46% on an annualized basis producing an average annual return of 16.88%. Currently, Molina Healthcare has a market capitalization of $17.49 billion. 
Buying $1000 In MOH: If an investor had bought $1000 of MOH stock 10 years ago, it would be worth $4,893.65 today based on a price of $322.79 for MOH at the time of writing.
<h3>Molina Healthcare's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1746463514_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Comments

Molina Healthcare

Actualités

Dernières nouvelles pour Molina Healthcare (NYSE:MOH) Stock

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL